Skip to main content
SpringerLink
Log in

The influence of vasopressin deficiency and acute desmopressin administration on melatonin secretion in patients with central diabetes insipidus

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Melatonin secretion is modulated by the light-dark schedule, mainly through a sympathetic input to the pineal gland. Besides this, arginine vasopressin (AVP) has been found in the pineal glands of several animal species and there is experimental evidence that AVP modulates melatonin secretion in animals. However, the interaction between vasopressin and melatonin secretion in humans has not been systematically investigated. We proposed to study the nocturnal melatonin pattern in patients with central diabetes insipidus (CDI) who lack endogenous secretion of AVP, and the effect on their melatonin secretion of the agonist for V2 type receptors: desmopressin (1-Desamino [8-D Arginine] vasopressin). Plasma melatonin levels were measured in 14 patients with CDI, every 2 h starting from 22:00 h until 06:00 h, following iv injection of saline (day 1) and 3 μg desmopressin (day 2) at 20:00 h. The lights were turned off at 22:30 h and the samples were taken in a dim light. The plasma melatonin secretion pattern was normal in patients with CDI. Desmopressin at a dose 3 times higher than the antidiuretic one did not modify the melatonin levels or the time of the peak secretion. In conclusion melatonin secretion is not modulated by AVP in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Larsen PJ, Enquist LW, Card JP. Characterization of the multisynaptic neuronal control of the rat pineal gland using viral transneuronal tracing. Eur J Neurosci 1998, 10: 128–45.

    Article  CAS  PubMed  Google Scholar 

  2. Teclemariam-Mesbah R, Ter Horst GJ, Postema F, Wortel J, Buijs RM. Anatomical demonstration of the suprachiasmatic nucleus-pineal pathway. J Comp Neurol 1999, 406: 171–82.

    Article  CAS  PubMed  Google Scholar 

  3. Moller M, Baeres FM. The anatomy and innervation of the mammalian pineal gland. Cell Tissue Res 2002, 309: 139–50.

    Article  CAS  PubMed  Google Scholar 

  4. Harmar AJ. An essential role for peptidergic signalling in the control of circadian rhythms in the suprachiasmatic nuclei. J Neuroendocrinol 2003, 15: 335–8.

    Article  CAS  PubMed  Google Scholar 

  5. Ingram CD, Ciobanu R, Coculescu IL, Tanasescu R, Coculescu M, Mihai R. Vasopressin neurotransmission and the control of circadian rhythms in the suprachiasmatic nucleus. Prog Brain Res 1998, 119: 351–64.

    Article  CAS  PubMed  Google Scholar 

  6. Buijs RM, Pevet P. Vasopressin- and oxytocin-containing fibres in the pineal gland and subcommissural organ of the rat. Cell Tissue Res 1980, 205: 11–7.

    Article  CAS  PubMed  Google Scholar 

  7. Nurnberger F, Korf HW. Oxytocin- and vasopressin-immunoreactive nerve fibers in the pineal gland of the hedgehog, Erinaceus europaeus L. Cell Tissue Res 1981, 220: 87–97.

    Article  CAS  PubMed  Google Scholar 

  8. Reppert SM, Coleman RJ, Heath HW, Keutmann HT. Circadian properties of vasopressin and melatonin rhythms in cat cerebrospinal fluid. Am J Physiol 1982, 243: E489–E498.

    CAS  PubMed  Google Scholar 

  9. Simonneaux V, Kozak R, Arsenijevic Y, Pevet P. Vasopressin potentiation of the melatonin synthetic pathway via specific V1a receptors in the rat pineal gland. Regul Pept 1996, 61: 63–9.

    Article  CAS  PubMed  Google Scholar 

  10. Isobe Y, Fujioi J, Nishino H. Circadian rhythm of melatonin release in pineal gland culture: arg- vasopressin inhibits melatonin release. Brain Res 2001, 918: 67–73.

    Article  CAS  PubMed  Google Scholar 

  11. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998, 449: 251–76.

    Article  CAS  PubMed  Google Scholar 

  12. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103: 228–39.

    Article  CAS  PubMed  Google Scholar 

  13. Saito M, Tahara A, Sugimoto T. 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol 1997, 53: 1711–7.

    Article  CAS  PubMed  Google Scholar 

  14. Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970, 73: 721–9.

    Article  CAS  PubMed  Google Scholar 

  15. Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders. 5th ed. New-York: McGraw-Hill, 2001.

    Google Scholar 

  16. Brismar K, Hylander B, Eliasson K, Rossner S, Wetterberg L. Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Med Scand 1988, 223: 525–30.

    Article  CAS  PubMed  Google Scholar 

  17. Kabuto M, Namura I, Saitoh Y. Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans. Endocrinol Jpn 1986, 33: 405–14.

    Article  CAS  PubMed  Google Scholar 

  18. Forsling ML, Montgomery H, Halpin D, Windle RJ, Treacher DF. Daily patterns of secretion of neurohypophysial hormones in man: effect of age. Exp Physiol 1998, 83: 409–18.

    CAS  PubMed  Google Scholar 

  19. Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med 1981, 305: 1539–46.

    Article  CAS  PubMed  Google Scholar 

  20. Coculescu M, Pavel S. Arginine vasotocin-like activity of cerebrospinal fluid in diabetes insipidus. J Clin Endocrinol Metab 1973, 36: 1031–2.

    Article  CAS  PubMed  Google Scholar 

  21. Stehle J, Reuss S, Riemann R, Seidel A, Vollrath L. The role of arginine-vasopressin for pineal melatonin synthesis in the rat: involvement of vasopressinergic receptors. Neurosci Lett 1991, 123: 131–4.

    Article  CAS  PubMed  Google Scholar 

  22. Bojanowska E, Forsling ML. The effects of melatonin on vasopressin secretion in vivo: interactions with acetylcholine and prostaglandins. Brain Res Bull 1997, 42: 457–61.

    Article  CAS  PubMed  Google Scholar 

  23. Forsling ML, Wheeler MJ, Williams AJ. The effect of melatonin administration on pituitary hormone secretion in man. Clin Endocrinol (Oxf) 1999, 51: 637–42.

    Article  CAS  Google Scholar 

  24. Barassin S, Kalsbeek A, Saboureau M, et al. Potentiation effect of vasopressin on melatonin secretion as determined by trans-pineal microdialysis in the Rat. J Neuroendocrinol 2000, 12: 61–8.

    Article  CAS  PubMed  Google Scholar 

  25. Simonneaux V, Ouichou A, Burbach JP, Pevet P. Vasopressin and oxytocin modulation of melatonin secretion from rat pineal glands. Peptides 1990, 11: 1075–9.

    Article  CAS  PubMed  Google Scholar 

  26. Furuta H, Luo L, Ryan AF, Mori N. Expression of mRNA encoding vasopressin V1a, vasopressin V2, and ANP-B receptors in the rat cochlea. Hear Res 1998, 117: 140–8.

    Article  CAS  PubMed  Google Scholar 

  27. Hirasawa A, Nakayama Y, Ishiharada N, et al. Evidence for the existence of vasopressin V2 receptor mRNA in rat hippocampus. Biochem Biophys Res Commun 1994, 205: 1702–6.

    Article  CAS  PubMed  Google Scholar 

  28. Ostrowski NL, Lolait SJ, Young WS, III. Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinology 1994, 135: 1511–28.

    CAS  PubMed  Google Scholar 

  29. Rahmani HR, Muge DK, Ingram CD. Pharmacological characterisation of oxytocin binding sites in the ovine pineal gland. Regul Pept 1997, 70: 23–7.

    Article  CAS  PubMed  Google Scholar 

  30. Werner S, Brismar K, Wetterberg L, Eneroth P. Circadian rhytms of Melatonin, Prolactin, Growth Hormone and Cortisol in Patients with Pituitary Adenomas, Emty Sella Syndrome and Cushing’s Syndrome due to Adrenal Tumours. In: Birau N, Schloot W, eds. Melatonin: Current Status and Perspectives. Oxford, New York: Pergamon Press. 1980, 357–63.

    Google Scholar 

  31. Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CA. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 2000, 85: 2189–96.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania

    S. B. Catrina M.D., Ph.D., R. Rotarus & M. Coculescu

  2. Department of Molecular Medicine, Karolinska Institute, M1:O2, Stockholm, S-17176, Sweden

    S. B. Catrina M.D., Ph.D., I-L. Wivall & K. Brismar

Authors
  1. S. B. Catrina M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Rotarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I-L. Wivall
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Coculescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Brismar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. B. Catrina M.D., Ph.D..

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Catrina, S.B., Rotarus, R., Wivall, IL. et al. The influence of vasopressin deficiency and acute desmopressin administration on melatonin secretion in patients with central diabetes insipidus. J Endocrinol Invest 27, 47–51 (2004). https://doi.org/10.1007/BF03350910

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350910

Key-words

Search

Navigation